Lumsden MA

No ORCID on file · 7 papers in corpus
rct 2023
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics ·doi:10.1002/ijgo.14626

OBJECTIVE: To determine treatment options (myomectomy vs. uterine artery embolization (UAE)) for women wishing to avoid hysterectomy. METHODS: A multicenter randomized controlled trial was conducted on 254 women and data were collected on …

rct 2023
EClinicalMedicine ·doi:10.1016/j.eclinm.2023.101995

BACKGROUND: Heavy menstrual bleeding affects one in four women and negatively impacts quality of life. Ulipristal acetate is prescribed to treat symptoms associated with uterine fibroids. We compared the effectiveness of ulipristal acetate …

observational 2020
BMC medicine ·doi:10.1186/s12916-020-01700-z

BACKGROUND: Women with diminished ovarian reserve are known to have increased cardiovascular risk, whether there is a continuous association between the ovarian reserve biomarkers; anti-Müllerian hormone (AMH), antral follicle count (AFC) a…

rct 2014
Trials ·doi:10.1186/1745-6215-15-468

BACKGROUND: Uterine fibroids are the most common tumour in women of reproductive age. By the time they are 50-years-old around 80% of women will have developed one. Of these, around half will experience symptoms which will impact negatively…

meta-analysis 2014
The Cochrane database of systematic reviews ·doi:10.1002/14651858.cd005073.pub4

BACKGROUND: Uterine fibroids cause heavy prolonged bleeding, pain, pressure symptoms and subfertility. The traditional method of treatment has been surgery as medical therapies have not proven effective. Uterine artery embolization has been…

observational 2001
BMJ (Clinical research ed.) ·doi:10.1136/bmj.323.7303.24

OBJECTIVES: To describe the menstrual experience of women referred for menstrual problems, in particular menorrhagia (excessive menstrual loss), and to assess associations with reasons for referral given by their general practitioners, the …

other 1990
Fertility and sterility ·doi:10.1016/s0015-0282(16)53217-8

Ten endometriosis patients received luteinizing hormone releasing hormone (LH-RH) agonist (buserelin) implant injections (6.6 mg subcutaneously) at days 0, 42, 84 and 126. Serum LH and follicle-stimulating hormone (FSH) were lowered by day …